ASCO - biotech
Kommentaari jätmiseks loo konto või logi sisse
-
15. mail algab USAs American Society of Clinical Oncology (ASCO), mis iga-aastane tippsündmus biotehnoloogiasektorile.
See toob kindlasti mitmeid suuri liikumisi ja mõjutab kogu sektorit. Liikumiste ootuses on juba hakatud volatiilsust kõrgemale kruvima ja panuseid tegema.
Näiteks ostis keegi eile Eyetechi (EYET) putte väga suure koguse, juuni 22.5 putte osteti 12 000, mis on mitmeid kordi suurem kui open interest enne seda oli.
Raske öelda, kas panustatakse puhtalt langusele või kindlustatakse aktsiapositsioone, kuid lõhnab pigem esimese järgi. -
Ja silmatüüpidel on ARVO.
sB -
arvol see aasta ka eesti firma kohal. asper biotech oma silmaharuga www.asperophthalmics.com
-
EYET puhul kardetakse enim DNA uut ravimit Lucentis, mille katsetustulemused peaks tulema 2Q-3Q. Otsene konkurent EYETi Macugenile. Mõned usuvad, et EYET võib selle peale liikuda
-20% - +60%. -
DNDN esmaspäeval suure tõenäosusega rallimas
Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival in Advanced... [FCQPQGY]
Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival
in Advanced Prostate Cancer Patients Presented at ASCO
ORLANDO, Fla., May 14 /PRNewswire-FirstCall/ -- Dendreon Corporation
(Nasdaq: DNDN) announced today that, as previously reported at the ASCO
Prostate Cancer Symposium in February, Provenge(R), the Company's
investigational immunotherapy for the treatment of prostate cancer,
significantly improved survival in men with asymptomatic, metastatic
androgen-independent (hormone-refractory) prostate cancer when compared to
patients receiving placebo. The study was presented today at the 2005
American Society of Clinical Oncology (ASCO) Annual Meeting by Eric J. Small,
M.D., professor of medicine and urology at the University of California, San
Francisco.
Dr. Small presented the final three-year intent-to-treat analysis of the
Company's first randomized Phase 3 clinical study, known as Study D9901. In
Study D9901, patients receiving Provenge had a median survival of 25.9 months
compared to 21.4 months for patients in the placebo arm, a 4.5 month
improvement (p-value = 0.01, hazard ratio = 1.7). This hazard ratio implies
that patients receiving placebo have a relative risk of dying that is
70 percent higher than those patients receiving Provenge. In addition,
34 percent of patients receiving Provenge were alive at 36 months compared to
11 percent of patients receiving placebo (p-value = 0.0046). Provenge was
well tolerated with the most common adverse events reported being fever and
chills lasting for one to two days.
For the first time, Dr. Small also presented new data from an analysis of
subsequent therapy that men received after their disease had progressed.
Pursuant to the D9901 study protocol, at the time patients in the study
developed objective disease progression, they were then treated at their
physician's discretion, including the use of chemotherapy. The results of
this additional analysis showed that there were no imbalances between the two
treatment arms of the trial with regard to the subsequent use of chemotherapy.
This was true for both docetaxel (Taxotere(R))-based regimens, as well as
other chemotherapy-based regimens. In addition, Dr. Small presented new data
from a commonly performed statistical analysis, known as a Cox regression
multivariate analysis, to further test the validity of the survival benefit
seen in this study. The results of this analysis confirm that the survival
benefit observed in this study was not due to any imbalances in the patient
population.
"These important additional analyses give us more confidence in the
survival outcome we observed in this trial and further underscore the
potential utility Provenge may have in this patient population for which few
appealing treatment options exist," said Dr. Small. "A targeted agent with
this type of survival benefit, combined with a favorable safety profile, has
the potential to provide an important new treatment option for prostate cancer
patients."
Study Details
The D9901 study was a double-blind, placebo-controlled Phase 3 trial
evaluating Provenge in men with asymptomatic, metastatic androgen independent
prostate cancer. The study was designed to measure time to disease
progression and time to development of disease-related pain in men with
androgen independent prostate cancer. In addition, a 36 month final survival
analysis was required per the study design. The study was conducted at 19
institutions in the United States and enrolled 127 men to receive three
infusions of Provenge or placebo over a four-week period. -
DNDN-l üle 13 milli aktsia lühikeseks müüdud. Valus saab see neile homme olema.
-
"...As previously reported at the ASCO Prostate Cancer Symposium in February.."
Üht-teist huvitavat siiski oli. Kirjutan veidi aja pärast Pro all lähemalt.
sB -
Et nüüd tahetakse kombineerida kaks miinust kokku üheks plussiks :)
NEW YORK, Aug 21 (Reuters) - OSI Pharmaceuticals
said on Sunday it agreed to buy eye disease treatment maker
Eyetech Pharmaceuticals Inc.for around $935 million in
cash and stock.
OSI will buy all outstanding Eyetech common shares for $20
each, the companies said -- a 43 percent premium to Eyetech's
Aug. 19 closing price of $13.99.
The agreement calls for 75 percent of the purchase price, or
$15 per share, to be paid in cash with the rest to be paid in
OSI common stock using an exchange ratio of 0.12275 OSI shares
for each Eyetech share.
